Companies › Neuraptive Therapeutics
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 2; Other; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NTX-001 (PEG-Fusion) Polyethylene glycol (PEG)-based nerve fusion product applied topically to enhance peripher | – | Phase 3 | Peripheral Nerve Injury Upper Limb; Peripheral Nerve Injuries | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06616025 | NTX-001 (PEG-Fusion) | Phase 3 | Peripheral Nerve Injury Upper Limb | Other | Mar 2027 |
| NCT04789044 | NTX-001 (PEG-Fusion) | Phase 2 | Peripheral Nerve Injuries | Other | Oct 2027 |
No annotated target.
–
Huons Biopharma Neuren Pharmaceuticals Tetra Discovery Partners Prove pharm Primus Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.